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Objective: To estimate visual impairment (VI) and blindness avoided with intravitreal ranibizumab 0.3 mg
treatment for central-involved diabetic macular edema (DME) among Hispanic and non-Hispanic white individuals
in the United States.
Design: Population-based model simulating visual acuity (VA) outcomes over 2 years after diagnosis and
treatment of DME.
Participants: Visual acuity changes with and without ranibizumab were based on data from the RISE, RIDE,
and DRCR Network trials.
Methods: For the better-seeing eye, VA outcomes included VI, deﬁned as worse than 20/40 in the better-
seeing eye, and blindness, deﬁned as VA of 20/200 or worse in the better-seeing eye. Incidence of 1 or both
eyes with central-involved DME in 2010 were estimated based on the 2010 United States population, prevalence
of diabetes mellitus, and 1-year central-involved DME incidence rate. Sixty-one percent of incident individuals
had bilateral DME and 39% had unilateral DME, but DME could develop in the fellow eye.
Main Outcomes Measures: Cases of VI and blindness avoided with ranibizumab treatment.
Results: Among approximately 102 million Hispanic and non-Hispanic white individuals in the United States
45 years of age and older in 2010, an estimated 37 274 had central-involved DME and VI eligible for ranibizumab
treatment. Compared with no ranibizumab treatment, the model predicted that ranibizumab 0.3 mg every 4 weeks
would reduce the number of individuals with VI from 11 438 (95% simulation interval [SI], 7249e16 077) to 6304
(95% SI, 3921e8981), a 45% (95% SI, 36%e53%) reduction at 2 years. Ranibizumab would reduce the number
of incident eyes with VA worse than 20/40 from 16 910 (95% SI, 10 729e23 577) to 9361 (95% SI, 5839e13 245),
a 45% (95% SI, 38%e51%) reduction. Ranibizumab was estimated to reduce the number of individuals with legal
blindness by 75% (95% SI, 58%e88%) and the number of incident eyes with VA of 20/200 or worse by 76%
(95% SI, 63%e87%).
Conclusions: This model suggests that ranibizumab 0.3 mg every 4 weeks substantially reduces prevalence
of VI and legal blindness 2 years after initiating treatment among Hispanic and non-Hispanic white individuals in
the United States with central-involved DME that has caused vision loss. Ophthalmology 2015;122:982-
989 ª 2015 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material is available at www.aaojournal.org.Diabetic retinopathy and diabetic macular edema (DME) are
the leading causes of vision loss in working-age adults in the
United States.1 In persons with diabetes mellitus, severe
vision loss usually is associated with proliferative diabetic
retinopathy, whereas the leading cause of moderate vision
loss, a loss of 15 letters or more (doubling of the visual
angle), is macular edema.2 Macular edema is characterized
by swelling of the macula, the central part of the retina that
mediates high-resolution vision.3 In the Early Treatment
Diabetic Retinopathy Study, the risk of moderate vision loss
from clinically signiﬁcant macular edema assigned to no982  2015 by the American Academy of Ophthalmology.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inctreatment unless and until high-risk proliferative diabetic
retinopathy developed was 33% after 3 years of follow-up.2
Until recently, laser photocoagulation, as applied in the
Early Treatment Diabetic Retinopathy Study, was the
standard of care for treatment of clinically signiﬁcant
macular edema because it reduced the risk of 15-letter or
more loss (approximately 3 lines or more of visual acuity
[VA] on an Early Treatment Diabetic Retinopathy Study
chart) by 50%.2 However, 15% of treated patients were
estimated to lose vision,2 and in recent trials evaluating
focal/grid laser treatment among patients with some vision.
http://dx.doi.org/10.1016/j.ophtha.2014.12.007
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Figure 1. Flowchart showing the estimated total number of persons 45 years of age and older with central-involved diabetic macular edema (DME) causing
vision of 20/32 or worse approximate Snellen equivalent who would be considered for ranibizumab treatment in the United States in 2010.
Varma et al  Vision Loss Avoided with Ranibizumab for DMEloss associatedwithDME, vision improvementwas estimated
to occur in only approximately 30% of patients.4 More recent
study results show that intravitreal injections of anti-vascular
endothelial growth factor (VEGF) agents have been shown to
have a greater chance of avoiding vision loss and improving
vision.4e6
Given the impact of ranibizumab (Lucentis; Genentech,
Inc., South San Francisco, CA) on VA in patients with
DME, we undertook this study to estimate the number of
non-Hispanic white and Hispanic persons with DME in the
United States who may be able to avoid vision loss and
blindness with the use of ranibizumab treatment.
Methods
A population-based effectiveness model was developed to simulate
changes in VA with versus without treatment with ranibizumab
0.3 mg administered every 4 weeks in patients with central-
involved DME and VA of 20/32 or worse approximate Snellen
equivalent (deﬁned as best-corrected VA [BCVA] letter score of
78). Eyes with central-involved DME but with vision better than
20/32 approximate Snellen equivalent were assumed not to be
candidates for ranibizumab treatment at this time. Speciﬁcations for
model parameters are listed in Table 1.
Estimate of Patients with Central-Involved Diabetic
Macular Edema for Whom Ranibizumab Treatment
Would Be Considered
The steps carried out to estimate the total number of patients with
central-involved DME in the United States for whom ranibizumab
treatment would be considered at this time are summarized in
Figure 1. First, only non-Hispanic white and Hispanic individuals
were considered in the model because the incidence of DME was
available for these groups, but not for other racial or ethnic groups.
Using data from the 2010 United States Census Bureau, individuals
45 years of age and older were stratiﬁed into 10-year age groups.7
In step 2, the prevalence of self-reported diabetes was obtained
from National Health and Nutrition Examination Survey 2005
through 2008 data.8 Next (step 3), the 1-year incidence ofcentral-involved DME for non-Hispanic white individuals was
derived from the Wisconsin Epidemiologic Study of Diabetic
Retinopathy,9 and that for Hispanics was derived from the Los
Angeles Latino Eye Study (LALES).10 Cases of DME that did
not involve the center of the macula or VA better than 20/32
approximate Snellen equivalent in the incident eye were
excluded. The proportion of incident eyes with central-involved
DME that had VA 20/32 or worse approximate Snellen equiva-
lent (BCVA letter score 78) was estimated using data from
LALES. Because we did not have access to the Wisconsin
Epidemiologic Study of Diabetic Retinopathy data, the same pro-
portion of incident eyes with central-involved DME with VA 20/32
or worse approximate Snellen equivalent from LALES was applied
for non-Hispanic white individuals. Next (step 4), individuals
without health insurance were excluded by assuming that they were
unlikely to have access to ranibizumab. The percentage of the
uninsured United States population by age and race or ethnic
groups was derived from a population survey conducted by the
United States Census Bureau in 2010.11 Finally (step 5), the total
number of persons eligible for treatment was derived by
summing across all age and race or ethnic groups. This ﬁnal
number then was used to simulate treatment with and without
ranibizumab 0.3 mg. These methods were repeated for treatment
with ranibizumab 0.5 every 4 weeks.
Estimated Rates of Visual Impairment and Blindness
The 2-year rates of visual impairment (VI) and blindness for both
the better-seeing eye and the incident eye were estimated using a
person-level simulation. Visual impairment was deﬁned as BCVA
letter score of 68 or fewer in the better-seeing eye, that is, an
approximate Snellen equivalent worse than 20/40.12 Legal
blindness was deﬁned as a BCVA letter score of 38 or fewer in
the better-seeing eye, that is, an approximate Snellen equivalent
20/200 or worse.12
The model was conducted as a 2-dimensional Monte Carlo
simulation to account for various sources of patient-level vari-
ability and parameter uncertainty using TreeAge Pro 2009 soft-
ware (TreeAge Software, Inc., Williamstown, MA). To achieve
stable rates, 300 averages of 280 simulated patients (based on the
sample size of relevant patients in A Study of Ranibizumab In-
jection in Subjects with Clinically Signiﬁcant Macular Edema983
Figure 2. Bar graph showing the number of individuals with central-
involved diabetic macular edema and visual acuity of 20/32 or worse
approximate Snellen equivalent at baseline who had visual impairment in
the better-seeing eye after 2 years (n ¼ 37 274 treated patients). Visual
impairment was deﬁned as best-corrected visual acuity worse than 20/40
approximate Snellen equivalent in the better-seeing eye. SI ¼ simulation
interval.
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Mellitus [RISE; clinicaltrials.gov identiﬁcation, NCT00473330],
A Study of Ranibizumab Injection in Subjects with Clinically
Signiﬁcant Macular Edema [ME] with Center Involvement Sec-
ondary to Diabetes Mellitus [RIDE; clinicaltrials.gov identiﬁca-
tion, NCT00473382], and the Diabetic Retinopathy Clinical
Research [DRCR] Network [clinicaltrials.gov identiﬁcation,
NCT00445003]) were sampled.4,6 For each simulated person, the
VA of the incident DME eye at baseline was sampled from the
VA distribution of participants in the DRCR Network.4 Sixty-one
percent of these individuals had bilateral central-involved DME;
therefore, the fellow eye VA also was sampled from the VA
distribution of participants in the DRCR Network.4
Approximately 39% of individuals were assumed not to have
central-involved DME in their fellow eye at the start of the
model, but could develop the condition over the 2-year period of
the model. For the fellow eye without central-involved DME, the
VA was sampled from the VA distribution of the fellow eye of
individuals in the DRCR Network who did not have DME in the
fellow eye. In the incident eye, the letter score change over 2
years was conditioned on the individual’s baseline VA. For
persons with baseline BCVA letter score of 73 or fewer (20/32 or
worse), the 2-year letter score change was based on RISE and
RIDE data. However, for baseline BCVA letter score of 78 to 74
(approximate Snellen equivalent of 20/32), the 2-year letter score
change was based on data from the DRCR Network because the
RISE and RIDE clinical trials did not include a sufﬁcient number
of participants in this VA range. Moreover, because the DRCR
Network protocol did not include ranibizumab 0.3 mg every 4
weeks dosing, we applied data from the ranibizumab 0.5 mg as-
needed arms and assumed that the efﬁcacy was comparable with
ranibizumab 0.3 mg every 4 weeks. The sampling distribution
was on the actual patient-level data rather than a ﬁtted distribution
based on assumption. For the fellow eye, the letter score change
over 2 years was conditioned on both the patient’s DME status of
the fellow eye and baseline VA. The risk of death was applied
using United States age-speciﬁc mortality rates.13 The mortality
rate of people with diabetes was calculated by adjusting the
overall mortality rate by a relative rate of mortality among
patients with diabetes compared with people without diabetes.14
The simulation also accounted for the patient’s risk of
treatment discontinuation every 4 weeks. While not receiving
treatment, no further changes in BCVA were assumed;
therefore, BCVA remained constant from the time of
discontinuation to month 24.
Estimated Cases of Visual Impairment and Blindness
The predicted cases of patients with central-involved DME who
had VI or worsened to blindness at month 24 were derived by
applying the rates of these outcomes to the size of the treatment-
eligible population. Calculations were performed for each age
stratum, then summed across. This population-level simulation was
carried out in @Risk software version 6.0 (Palisade Corporation,
Ithaca, NY) using 10 000 iterations, accounting for parameter
uncertainty, to estimate the conﬁdence in the results expressed as a
95% simulation interval (SI). The difference in outcomes between
the scenario without ranibizumab and the scenario with ranibizu-
mab 0.3 mg was calculated to determine the cases of VI or legal
blindness that were avoided. The percent reduction was calculated
as the percent change in the cases with the outcome at 2 years with
ranibizumab treatment.
Sensitivity analyses were carried out on the following param-
eters: (1) proportion of incident eyes with central-involved DME
that had VA of 20/32 or worse and (2) proportion of patients with
incident central-involved DME with VA of 20/32 or worse who984also had DME in the fellow eye with VA of 20/32 or worse at
baseline.Results
Among approximately 102 million non-Hispanic white and His-
panic individuals 45 years of age or older in the United States in
2010, an estimated total of 37 274 (95% SI, 23 753e51 802) pa-
tients with a diagnosis of central-involved DME with VA of 20/32
or worse Snellen equivalent were eligible for ranibizumab treat-
ment. For these 37 274 eligible individuals, VI in the better-seeing
eye was predicted in 11 438 (95% SI, 7249e16 077) who did not
receive ranibizumab treatment over 2 years (Fig 2). Over the same
period, ranibizumab 0.3 mg every 4 weeks reduced VI to 6304
(95% SI, 3921e8981) individuals, resulting in 5134 (95% SI,
3014e7659) for whom VI was avoided, or a 45% (95% SI,
36%e53%) reduction in VI.
Without ranibizumab treatment, 16 910 (95% SI, 10 729e23 577)
incident eyes with a BCVA worse than 20/40 were predicted over 2
years (Fig 3). Over the same period, ranibizumab 0.3 mg every 4
weeks reduced the number of incident eyes with a BCVA worse
than 20/40 to 9361 (95% SI, 5839e13 245), resulting in 7549
(95% SI, 4551e10 859) eyes avoiding an approximate Snellen
equivalent VA worse than 20/40, or a 45% (95% SI, 38%e51%)
reduction in VA worse than 20/40.
Legal blindness, deﬁned as BCVA of 20/200 or worse in the
better-seeing eye, was predicted in 1686 (95% SI, 987e2479) in-
dividuals not receiving ranibizumab treatment over 2 years (Fig 4).
Over the same period, treatment with ranibizumab 0.3 mg every
4 weeks reduced legal blindness to 411 (95% SI, 180e725)
individuals, resulting in 1275 (95% SI, 663e2025) persons for
whom legal blindness was avoided, or a 75% (95% SI,
58%e88%) reduction in legal blindness.
Figure 3. Bar graph showing the number of incident eyes with central-
involved diabetic macular edema and visual acuity of 20/32 or worse
approximate Snellen equivalent at baseline that had visual impairment
after 2 years (n ¼ 37 274 treated patients). Visual impairment was deﬁned
as best-corrected visual acuity worse than 20/40 approximate Snellen
equivalent in the incident eye with central-involved DME. SI ¼ simulation
interval.
Figure 5. Bar graph showing the number of incident eyes with central-
involved diabetic macular edema and visual acuity of 20/32 or worse
approximate Snellen equivalent at baseline that had visual acuity of 20/200
or worse after 2 years (n ¼ 37 274 treated patients). SI ¼ simulation
interval.
Varma et al  Vision Loss Avoided with Ranibizumab for DMEWithout ranibizumab treatment, 2673 (95% SI, 1597e3878)
incident eyes with a BCVA of 20/200 or worse were predicted over
2 years (Fig 5). Over the same period, treatment with ranibizumab
0.3 mg every 4 weeks reduced the number of incident eyes with a
BCVA of 20/200 or worse to 634 (95% SI, 313e1059), resulting
in 2040 (95% SI, 1124e3134) eyes in which VA of 20/200 or
worse was avoided, or a 76% (95% SI, 63%e87%) reduction in
VA 20/200 or worse.Figure 4. Bar graph showing the number of persons with central-involved
diabetic macular edema and visual acuity of 20/32 or worse approximate
Snellen equivalent at baseline who had legal blindness after 2 years
(n ¼ 37 274 treated patients). Legal blindness was deﬁned as best-corrected
visual acuity of 20/200 or worse in the better-seeing eye. SI ¼ simulation
interval.Sensitivity Analyses
The proportion (24.4%) of incident eyes with central-involved
DME that had a BCVA letter score of 78 or fewer (approximate
Snellen equivalent worse than 20/32) was based on only 41 inci-
dent cases of clinically signiﬁcant macular edema available in
LALES.8 The sensitivity of the results was tested by varying the base
value by 10% points. The resulting size of the treatment-eligible
population ranged between 21 991 (95% SI, 14 014e30 563) and
52 557 (95% SI, 33 492e73 041), corresponding to low (14.4%) and
high (34.4%) values of the sensitivity range. Table 2 shows the
impact of this change on VI in the better-seeing eye after 2
years. In addition, the results of varying the parameter control-
ling for the proportion of fellow eyes that also had DME with
BCVA letter score of 78 or fewer (approximate Snellen equiv-
alent of 20/32 or worse) at baseline are provided in Table 2.
Results for ranibizumab 0.5 mg every 4 weeks are available
in Table 3 (available at www.aaojournal.org).
Discussion
In this study, we developed a population-based model that
suggests that ranibizumab administered to patients with
DME in a manner similar to that described in the RIDE and
RISE studies would reduce the number of cases of VI by
45% (a reduction of 5134 individuals) and the number of
cases of legal blindness by 75% (a reduction of 1275 in-
dividuals). These estimates are based on the approximately
37 274 Hispanic and non-Hispanic white adults with DME
in the United States in whom ranibizumab treatment would
be indicated and potentially used. Similarly, when consid-
ering the number of eyes, regardless of the vision in the
fellow eye, VA worse than 20/40 would be avoided in 45%
of eyes (7549 eyes) and VA of 20/200 or worse would be
avoided in 76% of eyes (2040 eyes).985
Table 1. Speciﬁcations for Model Parameter Inputs
Model Parameter Value (Uncertainty or Variability) Source and Notes
Population size in 2010
Non-Hispanic white 2010 United States Census data7
45e54 yrs 31 141 170
55e64 yrs 27 277 532
65e74 yrs 16 940 823
75 yrs 15 268 608
Total 90 628 133
Hispanic 2010 United States Census7
45e54 yrs 5 463 528
55e64 yrs 3 213 817
65e74 yrs 1 648 718
75 yrs 1 132 906
Total 11 458 969
Prevalence of diabetes, % (SE)
Non-Hispanic white NHANES 2005e20088
45e54 yrs 6.4 (0.9)
55e64 yrs 10.8 (1.3)
65e74 yrs 18.1 (1.8)
75 yrs 14.4 (1.4)
Hispanic NHANES 2005e20088
45e54 yrs 14.4 (2.6)
55e64 yrs 24.6 (3.1)
65e74 yrs 29.3 (5.0)
75 yrs 25.1 (4.8)
Annual incidence of central-involved DME, mean (SE)
Non-Hispanic white 0.01308 (0.00271) WESDR9
Hispanic 0.01587 (0.00245) LALES10
Proportion of incident eyes with central-involved DME
with VA of 20/32 or worse (BCVA letter score
78), %
24.4 LALES10
Annual incidence of central-involved DME with VA of
20/32 or worse (BCVA letter score 78), mean (SE)
Non-Hispanic white 0.00319 (0.00066) Derived based on information from WESDR9 and
LALES10
Hispanic 0.00387 (0.00060) Derived based on information from WESDR9 and
LALES10
United States population without health insurance, % (SE)
Non-Hispanic white United States Census Bureau CPS11
45e54 yrs 13.5 (10.0)
55e64 yrs 11.0 (9.7)
65e74 yrs 1.3 (4.5)
75 yrs 0.6 (3.2)
Hispanics United States Census Bureau CPS11
45e54 yrs 37.0 (40.9)
55e64 yrs 31.4 (50.1)
65e74 yrs 10.1 (44.2)
75 yrs 6.4 (46.0)
Mortality rate
United States age-speciﬁc mortality rate United States Life Tables13
Relative rate of mortality (diabetes vs. nondiabetes) 2.31 Gregg 200714 (this factor was applied to overall
mortality rate to derive diabetes-speciﬁc mortality
rate)
Patients with incident central-involved DME with VA
20/32 or worse who also had DME in fellow eye
with VA 20/32 or worse at BL, %
60.6 Based on proportion of fellow eyes in RIDE and
RISE6 with DME and VA of 20/32 or worse
(BCVA letter score 78)
Probability of developing central-involved DME in
fellow eye (monthly)
0.0038 (SE ¼ 0.0013) 18.3% over 4 yrs, LALES10 probability for Hispanic
also was used for white population
Probability of ranibizumab discontinuation (monthly) 0.0068 RIDE and RISE6
BCVA at BL, mean letter score (SD)
Incident/treated DME eye 63.1 (11.1) DRCR Network4
Fellow eye without central-involved DME 71.7 (17.4) DRCR Network4 (used data from individuals
without DME in fellow eye)
Fellow eye had central-involved DME at BL or
developed central-involved DME
63.1 (11.1) DRCR Network4
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Table 1. (Continued.)
Model Parameter Value (Uncertainty or Variability) Source and Notes
BCVA change after 24 months mean letter score (SD)*
Incident eye with ranibizumab 0.3 mg 11.7 (11.2) RIDE and RISE6 for BL BCVA letter score 73;
DRCR Network for BL BCVA letter score 74e78
(note: only data for ranibizumab 0.5 mg available;
assumed efﬁcacy similar to ranibizumab 0.3 mg)
Incident eye without ranibizumab 2.0 (14.2) RIDE and RISE6 for BL BCVA letter score 73;
DRCR Network for BL BCVA letter score 74e78
Fellow eye without central-involved DME 0.5 (16.2) RIDE and RISE6 for BL BCVA letter score 73;
DRCR Network for BL BCVA letter score 74e78
Fellow eye with either central-involved DME at BL or
developed central-involved DME within 2 yrs,
mean letter score (SD)
Ranibizumab 0.3 mg 11.7 (11.2) Assumed to have similar efﬁcacy of
ranibizumab-treated study eye in RIDE, RISE,6
and DRCR Network. Actual BCVA change
depended on when central-involved DME
developed in the fellow eye and number of
months to end of model. Changes in BCVA are
assessed on a monthly basis.
No ranibizumab 2.0 (14.2)
BCVA letter score change per month if discontinued
from ranibizumab, mean
0.0 Assumed no further change in BCVA on
discontinuation of ranibizumab.
BCVA ¼ best-corrected visual acuity; BL ¼ baseline; CPS ¼ Current Population Survey; DME ¼ diabetic macular edema; DRCR ¼ Diabetic Retinopathy
Clinical Research; LALES ¼ Los Angeles Latino Eye Study; NHANES ¼ National Health and Nutrition Examination Survey; RIDE ¼ A Study of
Ranibizumab Injection in Subjects with Clinically Signiﬁcant Macular Edema (ME) with Center Involvement Secondary to Diabetes Mellitus; RISE ¼ A
Study of Ranibizumab Injection in Subjects with Clinically Signiﬁcant Macular Edema (ME) with Center Involvement Secondary to Diabetes Mellitus;
SD ¼ standard deviation; SE ¼ standard error; VA ¼ visual acuity; WESDR ¼ Wisconsin Epidemiologic Study of Diabetic Retinopathy.
*BCVA change after 24 months is conditioned on patient’s VA at BL.
Varma et al  Vision Loss Avoided with Ranibizumab for DMEThis model shows that with anti-VEGF treatment for
central-involved DME, the greatest impact is a reduction in
the number of persons with VI; however, preventing per-
sons with blindness may be modest because deterioration
of VA to this threshold is less likely to occur in DME. In
terms of relative reduction, a greater percent reduction in














Proportion of incident eyes with
central-involved DME that
had VA 20/32 or worse
(78 letter score)
No ranibizumab 24.4 11 438 (7249e16 077) 1
Ranibizumab 6304 (3921e8981)
Proportion of patients with
incident central-involved
DME with VA 20/32 or
worse (78 letter score)
who also had DME in fellow
eye with VA 20/32 or worse
(78 letter score) at
baseline
No ranibizumab 60.6 11 438 (7249e16 077) 5
Ranibizumab 6304 (3921e8981)
DME ¼ diabetic macular edema; VA ¼ visual acuity.with the percent reduction in those with VI. A similar
modeling approach conducted for anti-VEGF treatment in
individuals with age-related macular degeneration (AMD)
showed substantial reduction in both the cases of VI and of
blindness.15 Unlike in DME, individuals with AMD can
experience a rapid loss in VA without anti-VEGF ther-
apy. These models suggest that in the United States, withInvolved Diabetic Macular Edema Who Had Visual Impairment in
















4.4 6749 (4277e9485) 34.4 16 128 (10 221e22 669)
3719 (2314e5299) 8889 (5529e12 663)
0.6 10 036 (6548e13 896) 70.6 12 764 (8072e17 934)
5497 (3520e7714) 7052 (4411e10 026)
987
Ophthalmology Volume 122, Number 5, May 2015monthly ranibizumab treatment, AMD and DME may
eventually no longer be the leading causes of blindness
and VI in working-age (DME) and older (AMD)
Americans.
There were several limitations in this study. Our model
considered only incident cases of central-involved DME for
1 year (2010). Because incident cases from the second year
were not included, these results are conservative. Moreover,
other race or ethnic groups and prevalence cases of DME
were not included, which would substantially increase the
number of cases of VI and blindness avoided. The actual
VA of incident eye at the time of DME diagnosis in the
United States population is unknown. We applied the
baseline VA distribution from the DRCR Network. For in-
dividuals with baseline BCVA of 20/32 to 20/40 approxi-
mate Snellen equivalent, the VA change over 2 years, if
treated with ranibizumab 0.3 mg every 4 weeks, was
assumed to be similar to ranibizumab 0.5 mg as-needed as
used by the DRCR Network.4 Although persons with an
incident eye with BCVA of 20/32 to 20/40 are less likely
to experience marked gains in VA, the model is likely to
underestimate the gain based on ranibizumab as-needed
dosing instead of dosing every 4 weeks. Furthermore, this
model did not evaluate outcomes for ranibizumab admin-
istered less often than monthly for 2 years, in which
re-treatment and follow-up intervals were based on changes
in VA or OCT or both since the most recent injection.
However, in 2 other trials evaluating ranibizumab compared
with laser photocoagulation for central-involved DME
causing VI in which re-treatment and follow-up intervals
were based on changes in VA or OCT since the most recent
injection, VA outcomes were similar to those in RIDE and
RISE.4,5 This is especially evident when looking at sub-
groups with baseline VA averaging approximately 20/80,
similar to the baseline VA in RIDE and RISE. These similar
outcomes suggest that the projected beneﬁts of ranibizumab
treatment identiﬁed in our model likely would be similar if
alternative as-needed follow-up and re-treatment regimens
were followed, as was carried out in other studies that also
have shown that the VA beneﬁts are maintained as the
median number of treatments decreases to 3 to 4 in the
second year, 1 to 2 in the third year,16 0 to 1 in the fourth
year, and 0 in the ﬁfth year after initiating anti-VEGF
therapy.17
Finally, although we do not yet know how well this DME
model translates to clinical practice, the impact of anti-
VEGF therapy has been explored for AMD in a small
retrospective cohort study from Johns Hopkins University in
patients with incident neovascular AMD.18 Two cohorts
were identiﬁed: one from 2002, before the availability of
anti-VEGF therapy, and the other from 2008, after anti-
VEGF therapy became available. Substantial reductions in
the 2-year prevalences of blindness and VI after neovascular
AMD were observed in the cohort of patients treated in
2008 (where 98% were treated with anti-VEGF therapy)
compared with the cohort of patients treated in 2002 who
did not receive anti-VEGF therapy. Although there
are many limitations with retrospective cohort data, this
study suggests that these models may translate to clinical
practice.988In conclusion, using a simulation model of the United
States population of persons 45 years of age and older,
ranibizumab 0.3 mg every 4 weeks likely reduces legal
blindness at a rate of somewhere between 58% and 88% and
reduces VI at a rate between 36% and 53% at 2 years after
initiating treatment in non-Hispanic white and Hispanic in-
dividuals with central-involved DME causing some vision
loss. These projected beneﬁts of ranibizumab treatment are
particularly important given the potential for preventing
poor visual outcomes in eligible persons, including a sub-
stantial number of working-age adults in the United States.
References
1. Centers for Disease Control and Prevention. National diabetes
fact sheet: national estimates and general information on dia-
betes and prediabetes in the United States, 2011. Available at:
http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed
April 15, 2014.
2. Early Treatment Diabetic Retinopathy Study Research Group.
Photocoagulation for diabetic macular edema. Early Treatment
Diabetic Retinopathy Study report number 1. Arch Oph-
thalmol 1985;103:1796–806.
3. US Department of Health and Human Services; National Eye
Institute; National Institutes of Health. Diabetic retinopathy:
what you should know [NIH Publication No: 06-2171].
Available at: http://www.nei.nih.gov/health/diabetic/
diabeticretino.pdf. Accessed April 15, 2014.
4. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial
evaluating ranibizumab plus prompt or deferred laser or
triamcinolone plus prompt laser for diabetic macular edema.
Ophthalmology 2010;117:1064–1077.e35.
5. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The
RESTORE study: ranibizumab monotherapy or combined with
laser versus laser monotherapy for diabetic macular edema.
Ophthalmology 2011;118:615–25.
6. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab
for diabetic macular edema: results from 2 phase III ran-
domized trials: RISE and RIDE. Ophthalmology 2012;119:
789–801.
7. US Census Bureau. US Population Projections. National
population projections released 2008 (based on Census 2000).
Projected population by single year of age, sex, race, and
Hispanic origin for the United States: July 1, 2000 to July 1,
2050. Available at: http://www.census.gov/population/
projections/data/national/2008.html. Accessed April 13, 2014.
8. Centers for Disease Control and Prevention; National Center
for Health Statistics. National Health and Nutrition Examina-
tion Survey Data, 2005e2006 and 2007e2008. Available at:
http://www.cdc.gov/nchs/nhanes.htm. Accessed April 13,
2014.
9. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wis-
consin Epidemiologic Study of Diabetic Retinopathy. XV. The
long-term incidence of macular edema. Ophthalmology
1995;102:7–16.
10. Varma R, Choudhury F, Klein R, et al. Four-year incidence
and progression of diabetic retinopathy and macular edema:
the Los Angeles Latino Eye Study. Am J Ophthalmol
2010;149:752–761.e1e3.
11. US Census Bureau. Current Population Survey (CPS) 2011.
Current Population Survey (CPS) 2011 table creator. Health
insurance coverage for “White alone & Non-Hispanic,” and
“White alone & Hispanic.” Available at: http://www.census.
gov/cps/data/cpstablecreator.html. Accessed April 13, 2014.
Varma et al  Vision Loss Avoided with Ranibizumab for DME12. Centers for Disease Control and Prevention. The burden of
vision loss. Available at: http://www.cdc.gov/visionhealth/
basic_information/vision_loss_burden.htm. Accessed April
13, 2014.
13. Centers for Disease Control and Prevention, National Center
for Health Statistics. Life tables. Available at: http://www.cdc.
gov/nchs/data/nvsr/nvsr58/nvsr58_21.pdf. Accessed April 13,
2014.
14. Gregg EW, Gu Q, Cheng YJ, et al. Mortality trends in men and
women with diabetes, 1971 to 2000. Ann Intern Med
2007;147:149–55.
15. Bressler NM, Doan QV, Varma R, et al. Estimated cases
of legal blindness and visual impairment avoided using
ranibizumab for choroidal neovascularization:
non-Hispanic white population in the United States withage-related macular degeneration. Arch Ophthalmol
2011;129:709–17.
16. Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for
diabetic macular edema with prompt versus deferred laser
treatment: three-year randomized trial results. Ophthalmology
2012;119:2312–8.
17. Elman MJ, Ayala A, Bressler NM, et al; Diabetic Retinopathy
Clinical Research Network. Intravitreal ranibizumab for dia-
betic macular edema with prompt versus deferred laser treat-
ment: 5-year randomized trial results. Ophthalmology
2015;122:375–81.
18. Campbell JP, Bressler SB, Bressler NM. Impact of availability
of anti-vascular endothelial growth factor therapy on visual
impairment and blindness due to neovascular age-related
macular degeneration. Arch Ophthalmol 2012;130:794–5.Footnotes and Financial DisclosuresOriginally received: July 18, 2014.
Final revision: November 24, 2014.
Accepted: December 8, 2014.
Available online: February 7, 2015. Manuscript no. 2014-1133.
1 USC Eye Institute, Keck School of Medicine, University of Southern
California, Los Angeles, California.
2 Retina Division, Wilmer Eye Institute, Johns Hopkins University, Balti-
more, Maryland.
3 Outcomes Insights, Inc, Westlake Village, California.
4 Genentech, Inc, South San Francisco, California.
Presented at: American Society of Retina Specialists Annual Meeting,
August 2012, Las Vegas, Nevada; and the Association for Research in
Vision and Ophthalmology Annual Meeting, May 2012, Fort Lauderdale,
Florida.
Financial Disclosure(s):
The author(s) have made the following disclosure(s): R.V.: Consultant -
Allergan (Irvine, CA); Aquesys (Aliso Viejo, CA); Genentech, Inc (South
San Francisco, CA); Merck (Kenilworth, NJ); Replenish (Pasadena, CA);
Financial support - Genentech, Inc (South San Francisco, CA); Replenish,
(Pasadena, CA); unrestricted Departmental Grant from Research to Prevent
Blindness (New York, NY).
N.M.B.: Principal Investigator of grants at Johns Hopkins University,
sponsored by Bayer HealthCare Pharmaceuticals, Inc (Wayne, NJ); Gen-
entech/Roche (South San Francisco, CA); Novartis Pharma AG (Basel,
Switzerland); Regeneron Pharmaceuticals, Inc (Tarrytown, NY); The
EMMES Corporation (Rockville, MD); The National Institutes of Health,
(Bethesda, MD); N.M.B. has an independent contract agreement at Johns
Hopkins University from the American Medical Association (Chicago, IL).
Q.V.D.: Employee - Outcomes Insights, Inc (Westlake Village, CA);
Consultant - Genentech, Inc (South San Francisco, CA).
M.D.: Employee - Outcomes Insights, Inc (Westlake Village, CA);
Consultant - Genentech, Inc (South San Francisco, CA).A.L.: Employee - Outcomes Insights, Inc (Westlake Village, CA);
Consultant - Genentech, Inc (South San Francisco, CA).
C.M.D.: Consultant - Genentech, Inc (South San Francisco, CA).
A.T.: Employee - Genentech, Inc (South San Francisco, CA).
Genentech, Inc. (South San Francisco, CA) provided support for this study.
Support for third-party editorial assistance by Rebecca Jarvis, PhD, CMPP,
of Envision Scientiﬁc Solutions, was provided by Genentech, Inc. This
editorial support does not meet authorship criteria per International Com-
mittee of Medical Journal Editors guidelines, including no involvement in
study design, analysis, drafting, or critically reviewing the manuscript.
Genentech/Roche employees participated in the design of the study and in
revision of the manuscript, but the data management and data analysis were
performed by Outcomes Insights, Inc, independent of Genentech/Roche.
Genentech/Roche employees had access to the data before the completion
of data analysis.
Abbreviations and Acronyms:
AMD ¼ age-related macular degeneration; BCVA ¼ best-corrected visual
acuity; DRCR ¼ Diabetic Retinopathy Clinical Research; DME ¼ diabetic
macular edema; LALES ¼ Los Angeles Latino Eye Study; RIDE ¼ A
Study of Ranibizumab Injection in Subjects with Clinically Signiﬁcant
Macular Edema (ME) with Center Involvement Secondary to Diabetes
Mellitus; RISE ¼ A Study of Ranibizumab Injection in Subjects with
Clinically Signiﬁcant Macular Edema (ME) with Center Involvement
Secondary to Diabetes Mellitus; SI ¼ simulation interval; VA ¼ visual
acuity; VEGF ¼ vascular endothelial growth factor; VI ¼ visual
impairment.
Correspondence:
Rohit Varma, MD, MPH, USC Eye Institute, Keck School of Medicine,
University of Southern California, 1450 San Pablo Street, Suite 4900, Los
Angeles, CA 90033. E-mail: rvarma@usc.edu.989
